In the last year, few industries have captured cultural, regulatory, and investor interest to the same degree as prediction markets.

The companies best positioned for the next decade will not be those treating orphan drugs as isolated products, but those using rare disease as the commercial and regulatory proving ground for the next generation of biotech platforms.

In the 1980s, the US came to the conclusion that manufacturing and shipbuilding were commodity processes better suited for lower-cost labor markets in Asia.